Updated on
Summary The Food and Drug Administration has sent user-fee recommendations to Congress.
U.S. health regulators said on Friday they have submitted to Congress new recommendations for how manufacturers will help fund their review of new branded drugs, conventional generic medicines and a new generation of generic biotech treatments.At the same time, they have still not finalized how such user fee programs will apply to a review of medical devices.
